HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo before liver surgery aims to stop cancer's return
Disease control Not yet recruitingThis study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be randomly assigned to receive the drug combination bef…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
New drug combo aims to stop liver cancer from coming back after surgery
Disease control Not yet recruitingThis study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in people with early-stage but high-risk disease. About 30 adults with resectable stage IB or IIA hepatocellular car…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Gut bacteria may boost liver cancer treatment before surgery
Disease control Not yet recruitingThis study explores whether taking a probiotic (Lactobacillus reuteri) before surgery, alongside standard immunotherapy, can help liver cancer patients recover better and live longer. Forty adults with resectable liver cancer will be randomly assigned to receive either the probio…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New study aims to perfect radiation dose for liver cancer patients
Disease control Not yet recruitingThis study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy tumors using a treatment called Yttrium-90 radioembolization. About 30 adults will take part to help improve how this …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Liver cancer breakthrough: surgery or maintenance after successful conversion therapy?
Disease control Not yet recruitingThis study looks at 100 adults with liver cancer that was initially too advanced for surgery but shrank after conversion therapy. Researchers want to see if removing the remaining tumor with surgery is better than continuing maintenance therapy. The goal is to find which approach…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: West China Hospital • Aim: Disease control
Last updated May 26, 2026 11:57 UTC
-
New quadruple therapy aims to control liver cancer in diabetic patients
Disease control Not yet recruitingThis study tests a combination of four drugs (epalrestat, liver-directed chemotherapy, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this mix can stop the…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Haibo Shao • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Liver cancer breakthrough? drug combo before surgery may slash recurrence risk
Disease control Not yet recruitingThis study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in people with early-stage disease and a narrow surgical margin. About 60 adults with stage IA hepatocellular carcinoma will either receive the drug…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Could amino acids boost liver cancer treatment?
Disease control Not yet recruitingThis study tests whether adding branched-chain amino acids (BCAAs) to the standard drug combination of lenvatinib and pembrolizumab helps adults with liver cancer that cannot be removed by surgery. About 234 participants will be randomly assigned to receive the standard drugs wit…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo attack on tough liver cancer shows promise in early trial
Disease control Not yet recruitingThis study tests a combination of radiation therapy and two drugs (tislelizumab and anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein tumor thrombus). The goal is to shrink tumors and improve survival. About 27 adults wil…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for tough liver cancers: Nerve-Blocking technique added to standard therapy
Disease control Not yet recruitingThis study tests whether adding a nerve-blocking procedure (endovascular denervation) to standard treatments (TACE/HAIC and immune-targeted therapy) can help people with advanced liver cancer that has spread to the portal vein. The cancer must have gotten worse after initial trea…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New triple therapy aims to control advanced liver cancer without surgery
Disease control Not yet recruitingThis study tests a combination of three treatments—donafenib (a targeted drug), hepatic artery infusion chemotherapy (chemotherapy delivered directly to the liver), and sintilimab (an immunotherapy)—as the first treatment for people with unresectable hepatocellular carcinoma (liv…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New hope for tough liver cancers: triple therapy targets gene mutation
Disease control Not yet recruitingThis study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in 25 adults with advanced liver cancer that has a TP53 gene mutation and has not responded to previous immunotherapy. The goal is to see if the combination can shrink tumors and control the d…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Free rides and meals may help liver cancer patients start treatment
Symptom relief Not yet recruitingThis study looks at whether offering practical help—like free rides, temporary housing, and meal delivery—can reduce delays in starting cancer treatment for low-income people with liver cancer. About 75 adults who are uninsured or underinsured will be randomly assigned to receive…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated May 18, 2026 12:03 UTC
-
AI tool could help liver cancer patients avoid ineffective therapy
Knowledge-focused Not yet recruitingThis study aims to build an artificial intelligence system that can predict whether a person with advanced liver cancer will respond to a common drug combination (atezolizumab and bevacizumab). Researchers will look back at medical records and CT scans from 400 patients to find p…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated May 18, 2026 12:02 UTC